Bioventus (NYSE:BVS) Price Target Raised to $15.00

Bioventus (NYSE:BVS) had its price objective upped by Canaccord Genuity Group from $12.00 to $15.00 in a research note issued to investors on Wednesday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

Separately, Craig Hallum raised their target price on Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, September 27th.

Bioventus Stock Performance

BVS traded down $0.10 on Wednesday, hitting $11.18. 192,770 shares of the stock traded hands, compared to its average volume of 398,734. The business has a fifty day moving average price of $11.69 and a two-hundred day moving average price of $8.31. The company has a current ratio of 1.33, a quick ratio of 0.96 and a debt-to-equity ratio of 1.82. Bioventus has a 52 week low of $3.36 and a 52 week high of $14.38. The firm has a market capitalization of $905.29 million, a PE ratio of -18.49 and a beta of 0.88.

Bioventus (NYSE:BVS) last issued its earnings results on Tuesday, November 5th. The company reported $0.06 EPS for the quarter, hitting the consensus estimate of $0.06. Bioventus had a positive return on equity of 14.39% and a negative net margin of 7.82%. The firm had revenue of $138.96 million during the quarter, compared to analysts’ expectations of $132.57 million. During the same period last year, the business earned $0.05 earnings per share. On average, research analysts predict that Bioventus will post 0.4 EPS for the current fiscal year.

Insider Buying and Selling at Bioventus

In other news, Director John A. Bartholdson purchased 25,500 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The shares were acquired at an average cost of $8.55 per share, for a total transaction of $218,025.00. Following the transaction, the director now directly owns 6,939,357 shares of the company’s stock, valued at approximately $59,331,502.35. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. In related news, Director John A. Bartholdson acquired 80,000 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average cost of $8.55 per share, with a total value of $684,000.00. Following the transaction, the director now owns 6,913,857 shares of the company’s stock, valued at $59,113,477.35. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John A. Bartholdson acquired 25,500 shares of Bioventus stock in a transaction dated Monday, August 19th. The shares were purchased at an average cost of $8.55 per share, with a total value of $218,025.00. Following the completion of the transaction, the director now directly owns 6,939,357 shares of the company’s stock, valued at $59,331,502.35. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 32.90% of the company’s stock.

Hedge Funds Weigh In On Bioventus

A number of large investors have recently modified their holdings of BVS. Acadian Asset Management LLC bought a new stake in shares of Bioventus during the 1st quarter worth approximately $28,000. Lazard Asset Management LLC bought a new position in shares of Bioventus in the 1st quarter valued at about $40,000. HB Wealth Management LLC acquired a new position in shares of Bioventus during the 2nd quarter worth about $60,000. SG Americas Securities LLC acquired a new stake in Bioventus in the 1st quarter valued at about $66,000. Finally, Burns Matteson Capital Management LLC bought a new position in Bioventus during the second quarter worth about $67,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.